Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

BACKGROUND: Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety for the treatment of rheumatoid arthritis (RA) in randomized, controlled trials of up to 52 weeks’ duration. However, safety and effectiveness after long-term treatment have not been assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Tanaka, Sakae, Kawakami, Atsushi, Song, Yeong-Wook, Chen, Yi-Hsing, Rokuda, Mitsuhiro, Izutsu, Hiroyuki, Ushijima, Satoshi, Kaneko, Yuichiro, Nakashima, Yoshihiro, Shiomi, Teruaki, Yamada, Emi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068874/
https://www.ncbi.nlm.nih.gov/pubmed/32164762
http://dx.doi.org/10.1186/s13075-020-2125-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068874/
https://www.ncbi.nlm.nih.gov/pubmed/32164762
http://dx.doi.org/10.1186/s13075-020-2125-2

Ejemplares similares